Methamphetamine-dependence Clinical Trial
— tACS for MUDOfficial title:
tACS Intervention for Methamphetamine Addiction
Verified date | October 2023 |
Source | Shanghai Mental Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A growing body of evidence suggests a wide range of brain areas are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial alternating current stimulation (tACS) over prefrontal cortex reduces craving for meth dependences. In this study, the investigators investigated whether a current level of 15mA with a patented frequency of 77.5Hz tACS intervention of prefrontal cortex cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.
Status | Completed |
Enrollment | 23 |
Est. completion date | November 9, 2023 |
Est. primary completion date | May 9, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Methamphetamine dependents - middle school degree or above Exclusion Criteria: - Have contraindications to rTMS (head trauma, epilepsy or history of epilepsy, metal implant etc.) - psychiatric illnesses - intellectual impairment (IQ<90) |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantanghe Addiction Rehab Center | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Shanghai Mental Health Center |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | side effect measurements | The side effect is measured by Side effect scale, including ten types of adverse effects, such as headache, pricking, sleeplessness etc. The score ranged from 0 to 100, higher score indicates severe adverse effect. | every day after each intervention time for the 2 weeks intervention time period | |
Primary | Changes of Cue-induced craving | Subjective craving (cue induced, 0-100 based VAS, craving scale) | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | Changes of cognition: behavioral inhibition | using cognitive task: stop-signal task | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | Changes of cognition: choice under ambiguity | using cognitive task: choice under risk and ambiguity. The score of probability for risky choice is the major outcome, higher means more inclined to take risks. | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | changes of neural mechanism | based on resting-state EEG, the five power oscillations will be calculated (Delta band, Theta band, Alpha band, Beta band, and Gamma band). | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | Changes of depression status | the depression status is measured by Beck Depression inventory scale. The questionnaire is a 21-question multiple-choice self-report inventory, score ranged from 0 to 63, high score means worse depression. | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | Changes of anxiety status | Anxiety status is measured by Beck anxiety inventory scale,it consists of 21 self-reported items (four-point scale) used to assess the intensity of physical and cognitive anxiety symptoms. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). higher score means worse anxiety. | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | Changes of sleep status | sleep status measured by Pittsburgh Sleep Quality Index scale (PSQI). The global PSQI score is calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality. | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | Changes of impulsivity | Impulsivity is measured by Barratt Impulsiveness Scale, the total scores can range from 30 to 120. Higher score means higher impulsivity. | the day before intervention, 2 weeks after intervention, 3 months after intervention | |
Secondary | event-related potential in passive viewing task | Theamplitude of late positive potential (LPP) was considered as a major outcome of the drug-cue related ERP, higher LPP is related to higher craving. | the day before intervention, 2 weeks after intervention, 3 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT04449055 -
Pilot TMS for Methamphetamine Use Disorder
|
N/A | |
Active, not recruiting |
NCT05162391 -
Inflammation in Methamphetamine and STIs (IMSTI)
|
N/A | |
Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06233799 -
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
|
Phase 3 | |
Not yet recruiting |
NCT03748875 -
The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents
|
N/A | |
Recruiting |
NCT03341078 -
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
|
Phase 2 | |
Active, not recruiting |
NCT03910608 -
Paired Associative Stimulation in Methamphetamine Addiction
|
N/A | |
Terminated |
NCT05283304 -
Monthly Injectable BUP for MA Use Disorder (MURB) Trial
|
Phase 2 | |
Completed |
NCT04563962 -
Contingency Management for PrEP Adherence and/or Methamphetamine Use
|
N/A | |
Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A | |
Terminated |
NCT05034874 -
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
|
Phase 2 | |
Recruiting |
NCT06434818 -
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
|
Phase 2 | |
Recruiting |
NCT06027814 -
MHealth Incentivized Adherence Plus Patient Navigation
|
N/A | |
Completed |
NCT04544124 -
Delivering Contingency Management in Outpatient Addiction Treatment
|
N/A | |
Completed |
NCT01217970 -
Safety Interaction Trial Ibudilast and Methamphetamine
|
Phase 1 | |
Completed |
NCT03825536 -
Effect of Methamphetamine on Residual Latent HIV Disease Study
|
Phase 4 | |
Recruiting |
NCT03470480 -
rTMS for Craving in Methamphetamine Use Disorder
|
N/A | |
Recruiting |
NCT05128071 -
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
|
Early Phase 1 |